Emcure Pharma shares rise 7% after Q2 profit jumps 29%
In short
Emcure Pharmaceuticals shares rose as much as 7.3% after it said Q2 FY27 profit climbed 29.3% to Rs 325.1 crore. Revenue rose 24.3% and EBITDA rose 30.9%.
The market liked the update because growth was strong, especially overseas. The report does not give more details on what drove each business line.
What the reporting says
Emcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year rise in Q2 FY27 profit to Rs 325.1 crore. Revenue increased 24.3% and EBITDA rose 30.9%, according to the publisher summary, with strong international business growth cited as support. The immediate market reaction was positive, while the reporting does not provide further detail on segment performance or management outlook.
Why it matters
Emcure Pharmaceuticals saw its shares move higher after a Q2 FY27 update showed profit of Rs 325.1 crore, up 29.3% year on year. The summary also said revenue rose 24.3% and EBITDA increased 30.9%, with international business growth helping results. The move matters for Emcure shareholders and for pharma investors watching earnings momentum, but the reporting does not break out the sources of growth in detail.